Addition of Elotuzumab Ups PFS in Refractory Multiple Myeloma

WEDNESDAY, Nov. 7, 2018 -- For patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor has failed, progression-free survival is longer in those receiving the immunostimulatory monoclonal antibody elotuzumab in...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news